Vanda Pharmaceuticals (VNDA) Operating Leases (2019 - 2026)

Vanda Pharmaceuticals has disclosed Operating Leases across 8 years of filings, most recently posting $3.3 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $3.3 million, down 25.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 million (down 25.84% YoY), and the FY2025 annual result was $3.0 million, down 75.8% from the prior year.
• Operating Leases came in at $3.3 million for Q1 2026 at Vanda Pharmaceuticals, up from $3.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $12.4 million in Q4 2024 to a low of $3.0 million in Q4 2025.
• The 5-year median for Operating Leases is $7.5 million (2023), against an average of $7.0 million.
• Across the five-year window, Operating Leases surged 31.43% in 2024 and plunged 75.8% in 2025, its largest moves.
• Vanda Pharmaceuticals' Operating Leases stood at $8.8 million in 2022, then advanced by 6.71% to $9.4 million in 2023, then soared by 31.43% to $12.4 million in 2024, then slumped by 75.8% to $3.0 million in 2025, then increased by 9.19% to $3.3 million in 2026.
• The last three Operating Leases figures came in at $3.3 million (Q1 2026), $3.0 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.